Partnerships Torii/Shionogi (Japan; exclusive license for cantharidin products for molluscum and common warts; YCANTH/TO-208 approved in Japan Sep 2025, launched Feb 2026)
Indications
Molluscum contagiosum(Approved)
Common warts(Phase 2)
Status note First FDA-approved product for molluscum (Jul 2023, ages 2+); commercially launched in U.S. Aug 2023. Phase 2 COVE-1 in common warts completed; Type C meeting held. Cash of $11.2M at Jun 30, 2026 with $12.5M credit facility (PD Credit Agreement, Aug 2026).
Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Common Warts (Verruca Vulgaris); Common Warts; Human Papilloma Virus (HPV)
—
Sponsor-matched active trials from ClinicalTrials.gov (3 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.